



Eisai Inc. Medical Information

200 Metro Blvd. Nutley, NJ 07110

1-888-274-2378 • Fax: 732-791-1399 • <http://www.eisai.com/us>

International Kidney Cancer Symposium (IKCS) 2021, Hybrid Meeting; Austin, TX: Eisai Inc. Sponsored Research

Please see the listing of Eisai Inc. sponsored research presented at IKCS 2021 below and refer to the Congress Links section available on our Medical Information website which may include additional information.

RENAL CELL CARCINOMA

1. Motzer R, George S, Merchan JR, et al. Characterization and Management of Adverse Reactinos (ARs) in Patients with Advanced Renal Cell Carcinoma (aRCC) receiving Lenvatinib + Pembrolizumab (CLEAR Study). Poster presented at the the International Kidney Cancer Symposium (IKCS) 2021; November 5-6, 2021; Hybrid Meeting; Austin, Texas.
2. Choueiri TK, Powles T, Porta C, et al. A Phase 3 Trial of Lenvatinib Plus Pembrolizumab (LEN+PEMBRO) Versus Sunitinib as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma (aRCC): Overall Survival Follow-up Analysis (CLEAR study). Poster presented at the the International Kidney Cancer Symposium (IKCS) 2021; November 5-6, 2021; Hybrid Meeting; Austin, Texas.

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the publication(s) listed above, please submit your request via www.eisaimedicalinformation.com/oncology/medicalinquiry or the submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_oncmedinfo@eisai.com or call 1-888-274-2378.